{"id":"ptx-covid19-b","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine delivers lipid nanoparticle-formulated mRNA encoding coronavirus spike and other viral antigens, which are translated by host cells to generate immune recognition. This triggers both cellular and humoral immune responses to prevent or reduce severity of COVID-19 infection.","oneSentence":"PTX-COVID19-B is an mRNA vaccine that encodes viral proteins to stimulate immune responses against SARS-CoV-2.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:30:48.587Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention"}]},"trialDetails":[{"nctId":"NCT05175742","phase":"PHASE2","title":"PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine.","status":"COMPLETED","sponsor":"Providence Therapeutics Holdings Inc.","startDate":"2021-08-17","conditions":"Covid19 Vaccine","enrollment":565},{"nctId":"NCT05534035","phase":"PHASE3","title":"Booster Superiority Study of PTX-COVID19-B Compared to Vaxzevria® in Adults Aged 18 Years and Older","status":"UNKNOWN","sponsor":"Everest Medicines (Singapore) Pte. Ltd.","startDate":"2023-02-03","conditions":"SARS-CoV-2 Infection","enrollment":450},{"nctId":"NCT05534048","phase":"PHASE3","title":"Booster Study of PTX-COVID19-B in Adults Aged 18 Years and Older","status":"UNKNOWN","sponsor":"Everest Medicines (Singapore) Pte. Ltd.","startDate":"2023-02-03","conditions":"SARS-CoV-2 Infection","enrollment":3800},{"nctId":"NCT04765436","phase":"PHASE1","title":"PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64","status":"COMPLETED","sponsor":"Providence Therapeutics Holdings Inc.","startDate":"2021-01-14","conditions":"Covid19 Vaccine","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"PTX-COVID19-B","genericName":"PTX-COVID19-B","companyName":"Providence Therapeutics Holdings Inc.","companyId":"providence-therapeutics-holdings-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"PTX-COVID19-B is a messenger RNA (mRNA)-based COVID-19 vaccine intended for the prevention of COVID-19 in the general population. It is being studied in a clinical trial to demonstrate its safety, tolerability, and immunogenicity in comparison to the Pfizer-BioNTech COVID-19 vaccine and a placebo.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}